A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Terminated

• Conditions: Geographic Atrophy

• Registration Number: NCT02399072
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study also will generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling 200 participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 60 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-03-23
• Study First Submitted QC: 2015-03-23
• Study First Posted: 2015-03-26
• Study Start: 2015-03-30
• Primary Completion: 2018-02-08
• Study Completion: 2018-02-08
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-07
• Last Update Posted: 2019-08-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 202

Inclusion Criteria

• Well-demarcated area of GA secondary to AMD
• Women of childbearing potential and men must agree to use adequate contraception for at least 30 days after fluorescein dye administration
• The study is recruiting participants in two different cohorts:

Cohort 1: Participants with unilateral GA OR Cohort 2: Participants with GA in one eye and CNV (active or treated) with or without GA, in the contralateral eye

Exclusion Criteria

• Previous participation in any studies of investigational drugs for GA / dry AMD (exception for studies of vitamins and minerals)
• GA in either eye due to causes other than AMD
• History of vitrectomy surgery, submacular surgery, or any surgical intervention for AMD
• Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and/or proliferative diabetic retinopathy
• Any ocular/systemic medical conditions that, in the opinion of the investigator, could contribute to participant's inability to participate in the study or interfere with study assessments.
• Requirement for continuous use of therapy indicated in Prohibited Therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean Change from Baseline in the GA Area as Assessed by Fundus Autofluorescence (FAF) up to Month 60	Baseline up to Month 60

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Cards or Radner Reading Cards up to Month 60	Baseline up to Month 60
Change from Baseline in Monocular Reading Speed as Assessed by MNRead Cards or Radner Reading Cards up to Month 60	Baseline up to Month 60
Percentage of Participants With Medical Events	Baseline up to Month 60
Percentage of Participants With Ocular Events	Baseline up to Month 60
Change from Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart up to Month 60	Baseline up to Month 60
Change from Baseline in BCVA Score as Assessed by ETDRS Chart Under Low Luminance Conditions up to Month 60	Baseline up to Month 60
Change from Baseline in Binocular Critical Print Size as Assessed by MNRead Cards or Radner Reading Cards up to Month 60	Baseline up to Month 60
Change from Baseline in Monocular Critical Print Size as Assessed by MNRead Cards or Radner Reading Cards up to Month 60	Baseline up to Month 60
Change from Baseline in Near Activity Subscale as Assessed by National Eye Institute Visual Functioning Questionnaire 25-Item Version (NEI VFQ-25) up to Month 60	Baseline up to Month 60
Change from Baseline in Distance Activity Subscale as Assessed by NEI VFQ-25 up to Month 60	Baseline up to Month 60
Change from Baseline in Composite Scores as Assessed by NEI VFQ-25 up to Month 60	Baseline up to Month 60
Change from Baseline in Functional Reading Independence Score up to Month 60	Baseline up to Month 60

Trial Locations

Locations (63)

Retina Specialty Institute; 🇺🇸 Pensacola, Florida, United States

Midwest Vision Research Foundation; 🇺🇸 Chesterfield, Missouri, United States

Char Eye Ear &Throat Assoc; 🇺🇸 Charlotte, North Carolina, United States

Retina Assoc of Cleveland Inc; 🇺🇸 Cleveland, Ohio, United States

Palmetto Retina Center; 🇺🇸 Florence, South Carolina, United States

Tennessee Retina PC.; 🇺🇸 Nashville, Tennessee, United States

Retina Res Institute of Texas; 🇺🇸 Abilene, Texas, United States

Texas Retina Associates; 🇺🇸 Dallas, Texas, United States

Retina Consultants of Houston; 🇺🇸 The Woodlands, Texas, United States

Strategic Clinical Research Group, LLC; 🇺🇸 Willow Park, Texas, United States

Scroll for more (53 remaining)